The increasing prevalence of chronic diseases and the rising demand for controlled-release formulations are primarily expected to drive market growth.
The growing prevalence of chronic diseases significantly contributes to the expansion of the market. Chronic conditions such as diabetes, hypertension, and cardiovascular diseases require long-term management, often necessitating medications that provide stable therapeutic effects over extended periods. Sustained-release formulations can help achieve this by minimizing the frequency of dosing, which is particularly beneficial for patients who may struggle with adherence to multiple daily doses. According to the World Health Organization, nearly 41 million people die annually due to noncommunicable diseases, underscoring the urgent need for effective long-term treatment options, which sustained-release excipients can provide.
Sustained-release excipients are specialized substances used in pharmaceutical formulations designed to release a drug slowly over an extended period. These excipients help maintain consistent drug levels in the bloodstream, reducing the need for frequent dosing and enhancing patient compliance. They are essential in creating formulations that can effectively modulate the release profile of active pharmaceutical ingredients (APIs), ensuring that the medication remains effective for longer durations without causing dose dumping or rapid fluctuations in drug concentration.
These advancements not only improve the efficacy and safety of medications but also facilitate the production of more patient-friendly dosage forms, further stimulating market demand.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The global sustained-release excipients industry was valued at USD 1.4 billion in 2024 and is projected to grow at an 8.3% CAGR from 2025 to 2034, driven by the increasing prevalence of chronic diseases and rising demand for controlled-release formulations.
The polymers segment generated USD 435.2 million in revenue in 2024, as their versatility allows for tailored drug release profiles, meeting specific therapeutic needs.
The U.S. sustained-release excipients market is expected to reach USD 967.4 million by 2034, driven by a high prevalence of chronic diseases and the need for formulations that improve patient compliance.
Key players in the market include BASF, Ashland Global, Colorcon, Croda International, DFE Pharma, Eastman, Evonik Industries, FMC Corporation, Gattefosse, International Flavors & Fragrances, and JRS Pharma.